Abstract: A process for enzymatic production of glyceride compositions, specifically industrially practicable production of triglycerides, including conjugated linoleic and linolenic acid triglycerides, and the compositions produced by such process. An enzymatic reaction zone is first utilized, in which a mixture of glycerol and fatty acids or fatty acid derivatives is reacted in the presence of an enzymatic catalyst to form 1,3 diglycerides. The mixture is then circulated through a second thermal rearrangement zone, maintained at a higher temperature, to promote rearrangement of the 1,3 diglycerides to 1,2 diglycerides. Triglycerides are produced by re-circulating the mixture through the enzymatic production zone.

Abstract: A process for enzymatic production of glyceride compositions, specifically industrially practicable production of triglycerides, including conjugated linoleic and linolenic acid triglycerides, and the compositions produced by such process. An enzymatic reaction zone is first utilized, in which a mixture of glycerol and fatty acids or fatty acid derivatives is reacted in the presence of an enzymatic catalyst to form 1,3 diglycerides. The mixture is then circulated through a second thermal rearrangement zone, maintained at a higher temperature, to promote rearrangement of the 1,3 diglycerides to 1,2 diglycerides. Triglycerides are produced by re-circulating the mixture through the enzymatic production zone.

Abstract: A process to manufacture conjugated linoleic acid (CLA)-containing materials such as conjugated linoleic salts and acids that are enriched in desirable cis-9, trans-11- and trans-10, cis-12-CLA isomers and are low in certain undesirable isomers. The process generally entails isomerization of an alkyl ester of a linoleic acid-containing material at a temperature typically between about 90 to 140° C. to effectuate conjugation of the double bonds, followed by saponification of the resultant CLA-containing fatty acid ester to produce a CLA-containing fatty acid salt, optionally followed by neutralization of the CLA-containing fatty acid salt with an acid source to produce a CLA-containing fatty acid.

Abstract: A process to manufacture conjugated linoleic acid (CLA)-containing materials such as conjugated linoleic salts and acids that are enriched in desirable cis-9, trans-11- and trans-10, cis-12-CLA isomers and are low in certain undesirable isomers. The process generally entails isomerization of an alkyl ester of a linoleic acid-containing material at a temperature typically between about 90 to 140° C. to effectuate conjugation of the double bonds, followed by saponification of the resultant CLA-containing fatty acid ester to produce a CLA-containing fatty acid salt, optionally followed by neutralization of the CLA-containing fatty acid salt with an acid source to produce a CLA-containing fatty acid.

Abstract: A process to manufacture conjugated linoleic acid (CLA)-containing materials such as conjugated linoleic salts and acids that are enriched in desirable cis-9, trans-11- and trans-10, cis-12-CLA isomers and are low in certain undesirable isomers. The process generally entails isomerization of an alkyl ester of a linoleic acid-containing material at a temperature typically between about 90 to 140° C. to effectuate conjugation of the double bonds, followed by saponification of the resultant CLA-containing fatty acid ester to produce a CLA-containing fatty acid salt, followed by neutralization of the CLA-containing fatty acid salt with an acid source to produce a CLA-containing fatty acid.

Abstract: A storage stable porfimer sodium (polyhematoporphyrin ether/ester) composition useful in the photodynamic therapy of cancer and other conditions is provided. The composition is characterized in that the percentage of ester linked porphyrin oligomers is less than 10% of the composition. Improved processes for preparing such compositions are also provided wherein acetylated hematoporphyrin is treated with alkali for sufficient time and temperature to reduce the amount of porphyrin oligomers joined by ester linkages to less than 10% of the composition.

Abstract: A storage stable porfimer sodium (polyhematoporphyrin ether/ester) composition useful in the photodynamic therapy of cancer and other conditions is provided. The composition is characterized in that the percentage of ester linked porphyrin oligomers is less than 10% of the composition. Improved processes for preparing such compositions are also provided wherein acetylated hematoporphyrin is treated with alkali for sufficient time and temperature to reduce the amount of porphyrin oligomers joined by ester linkages to less than 10% of the composition.